Analyst Price Target is $72.63
▲ +114.68% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for ChemoCentryx in the last 3 months. The average price target is $72.63, with a high forecast of $107.00 and a low forecast of $38.00. The average price target represents a 114.68% upside from the last price of $33.83.
Current Consensus is
The current consensus among 8 investment analysts is to buy stock in ChemoCentryx. This Buy consensus rating has held steady for over two years.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA.